Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is Bronte Capital Management Pty Ltd.’s 3rd Largest Position

Bronte Capital Management Pty Ltd. lifted its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 2.8% during the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 145,421 shares of the biopharmaceutical company’s stock after buying an additional 3,979 shares during the quarter. Regeneron Pharmaceuticals makes up 12.2% of Bronte Capital Management Pty Ltd.’s holdings, making the stock its 3rd largest holding. Bronte Capital Management Pty Ltd. owned 0.13% of Regeneron Pharmaceuticals worth $127,722,000 at the end of the most recent quarter.

Other hedge funds also recently bought and sold shares of the company. Annis Gardner Whiting Capital Advisors LLC bought a new position in shares of Regeneron Pharmaceuticals in the third quarter worth about $26,000. Fortitude Family Office LLC bought a new stake in Regeneron Pharmaceuticals in the 4th quarter valued at $31,000. MCF Advisors LLC lifted its stake in Regeneron Pharmaceuticals by 50.0% in the 4th quarter. MCF Advisors LLC now owns 36 shares of the biopharmaceutical company’s stock worth $32,000 after purchasing an additional 12 shares in the last quarter. Criterion Capital Advisors LLC bought a new position in shares of Regeneron Pharmaceuticals during the 4th quarter valued at about $37,000. Finally, Sutton Wealth Advisors Inc. grew its position in shares of Regeneron Pharmaceuticals by 38.2% during the third quarter. Sutton Wealth Advisors Inc. now owns 47 shares of the biopharmaceutical company’s stock valued at $39,000 after purchasing an additional 13 shares in the last quarter. Institutional investors own 83.31% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on the company. Royal Bank of Canada restated an “outperform” rating and set a $1,189.00 price target on shares of Regeneron Pharmaceuticals in a report on Tuesday, April 9th. StockNews.com cut shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, April 30th. Morgan Stanley increased their price target on shares of Regeneron Pharmaceuticals from $1,104.00 to $1,115.00 and gave the company an “overweight” rating in a report on Wednesday, March 13th. Cantor Fitzgerald reissued a “neutral” rating and set a $925.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Friday, May 3rd. Finally, Barclays raised their price objective on Regeneron Pharmaceuticals from $935.00 to $1,020.00 and gave the company an “overweight” rating in a research note on Tuesday, January 23rd. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and sixteen have issued a buy rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $981.71.

Insider Activity

In related news, EVP Marion Mccourt sold 358 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Friday, March 1st. The shares were sold at an average price of $967.50, for a total transaction of $346,365.00. Following the transaction, the executive vice president now directly owns 13,431 shares of the company’s stock, valued at $12,994,492.50. The sale was disclosed in a filing with the SEC, which is accessible through this link. In related news, EVP Marion Mccourt sold 358 shares of the firm’s stock in a transaction dated Friday, March 1st. The stock was sold at an average price of $967.50, for a total transaction of $346,365.00. Following the sale, the executive vice president now owns 13,431 shares of the company’s stock, valued at $12,994,492.50. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Bonnie L. Bassler sold 854 shares of Regeneron Pharmaceuticals stock in a transaction dated Monday, February 26th. The shares were sold at an average price of $979.25, for a total value of $836,279.50. Following the completion of the transaction, the director now owns 1,382 shares in the company, valued at approximately $1,353,323.50. The disclosure for this sale can be found here. In the last quarter, insiders sold 8,095 shares of company stock worth $7,779,766. 8.83% of the stock is currently owned by corporate insiders.

Regeneron Pharmaceuticals Stock Up 1.3 %

Shares of Regeneron Pharmaceuticals stock traded up $12.24 during trading on Thursday, hitting $968.00. 281,944 shares of the stock traded hands, compared to its average volume of 493,490. The company has a current ratio of 5.27, a quick ratio of 4.51 and a debt-to-equity ratio of 0.10. The stock’s fifty day simple moving average is $942.03 and its 200 day simple moving average is $899.83. The firm has a market cap of $106.25 billion, a P/E ratio of 28.60, a price-to-earnings-growth ratio of 2.74 and a beta of 0.17. Regeneron Pharmaceuticals, Inc. has a 52-week low of $684.80 and a 52-week high of $998.33.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.